.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,858,650

« Back to Dashboard

Claims for Patent: 6,858,650

Title: Stable salts of novel derivatives of 3,3-diphenylpropylamines
Abstract:The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyr ate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.
Inventor(s): Meese; Claus (Monheim, DE)
Assignee: Schwarz Pharma AG (DE)
Application Number:10/130,214
Patent Claims: 1. Compounds of general formula I ##STR35##

in which R denotes C.sub.1 -C.sub.6 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl, substituted or unsubstituted phenyl and X.sup.- is the acid residue of a physiologically compatible inorganic or organic acid.

2. Compounds in accordance with claim 1, characterised in that X.sup.- in each case is an acid ester of hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(-)-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+) -tartaric acid, D-(-)-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicyclic acid, vanillic acid, 4-hydroxycinammic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-aectylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid.

3. Compounds in accordance with claims 1, characterised in that they have general formula 2: ##STR36##

in which R denotes C.sub.1 -C.sub.6 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl, substituted or unsubstituted phenyl and X.sup.- is the acid residue of a physiologically compatible inorganic or organic acid.

4. Compounds in accordance with claim 3, characterised in that X in each case is an acid ester of hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(-)-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(-)-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicyclic acid, vanillic acid, 4-hydroxycinammic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-aectylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid.

5. Compounds in accordance with claims 3, characterised in that they are R-(+)-2-(3-(diisopropylamino-1-phenylpropyl)-4-hydroxymethyl -phenylisobutyrate ester hydrogen fumarate, R-(+)-2-(3-(diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyr ate ester-hydrochloride hydrate.

6. Compounds in accordance with claims 3, characterised in that R stands for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-(1-cyclopropyl-methanoyloxy)-phenyl, 4-(1-cyclobutyl-methanoyloxy)-phenyl, 4-(1-cyclohexyl-methanoyloxy)-phenyl or 4-(2,2-dimethyl-propanoyloxy)-phenyl and X.sup.- denotes chloride.

7. Method for manufacturing compounds of general formula I ##STR37##

in which R denotes C.sub.1 -C.sub.6 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl, substituted or unsubstituted phenyl and X- is the acid residue of a physicologically compatible inorganic or organic acid, characterised in that a) a compound of formula III ##STR38##

is split with a hydrogenation agent to form a compound of Formula V ##STR39##

whereupon b) the compoud of formula V so obtained is converted with a reducing agent, in order to give a compound of formula VI ##STR40##

which c) is converted with an acylation agent, in order to obtain a compound of formula A ##STR41##

in which R has the significance stated above, which d) is converted with a physiologically compatible inorganic or organic acid to form a compound of formula I ##STR42##

in which R denotes C.sub.1 -C.sub.6 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl, unsubstituted or substituted phenyl and X- is the acid residue of a physiologically compatible inorganic or organic acid.

8. Method in accordance with claim 7, characterised in that for the manufacture of the compounds of general formula I hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(-)-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(-)-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicyclic acid, vanillic acid, 4-hydroxycinammic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-aectylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid are used.

9. Method for manufacturing compounds of general formula 2 ##STR43##

in which R denotes C.sub.1 -C.sub.6 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl, substituted or unsubstituted phenyl and X- is the acid residue of a physiologically compatible inorganic or organic acid, characterised in that a) a compound of the formula 3 ##STR44##

s split with a hydrogenation agent to form a compound of formula 5 ##STR45##

whereupon b) the compound formula 5 so obtained is converted with a reducing agent, in order to give a compound of formula 6 ##STR46##

which c) is converted with an acylation agent, in order to obtain a compound of formula 1 ##STR47##

in which R has the significance stated above, which d) is converted with a physiologically compatible inorganic or organic acid to form a compound of formula 2 ##STR48##

in which R denotes C.sub.1 -C.sub.6 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl, unsubstituted or substituted phenyl and X- is the acid residue of a physiologically compatible inorganic or organic acid.

10. Method in accordance with claim 9, characterised in that for the manufacture of the compounds of general formula 2 hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(-)-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(-)-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicyclic acid, vanillic acid, 4-hydroxycinammic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-aectylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid are used.

11. Method in accordance with claims 7, characterised in that as the hydrogenation agent, Raney nickel/H.sub.2 in methanol is preferably used as the solvent.

12. Method in accordance with claims 7, characterised in that for the reducing agent NaBH.sub.4 EtOH, preferably LiAlH.sub.4 /THF, is used.

13. Method in accordance with claims 7, characterised in that for the acylation agent isobutyrylchloride and for the base triethylamine are used.

14. Method in accordance with claims 9, characterised in that a compound of general formula 6 is converted with an equivalent isobutyryl chloride in the presence of triethylamine using one of the respective solvents ethylacetate, dichloromethane, tetrahydrofurane, acetonitrile or toluene regio- and chemoselectively into R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te.

15. Method in accordance with claims 9, characterised in that R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te ester and fumaric acid or hydrochloric acid are converted with the formation of the respective salt.

16. Method in accordance with claims 9 for the manufacture of R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxy-methylphenylisobuty rate ester hydrochloride hydrate, characterised in that the phenolic esterification of R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxy-methylphenol (6) is carried out without the addition of an external base, in that solutions of (6) are dropped into solutions of isobutyryl chloride, that contain at least 1 mole equivalent of water, in order to directly obtain a corresponding stable, hydrate-containing hydrochloride.

17. Compound of formula 7 ##STR49##

18. A method of manufacture of phenolic monoesters of general formula 1 ##STR50##

wherein the method comprises the steps of: providing a compound of claim 17; deprotecting the hydroxyl residues of the 4-hydroxy-benzyl alcohol residue; and acylating the phenol residue.

19. A method of manufacture of salts of phenolic monoesters of general formula 2: ##STR51##

in which R denotes C.sub.1 -C.sub.6 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl, substituted or unsubstituted phenyl and X.sup.- is the acid residue of a physicologically compatible inorganic or organic acid, wherein the method comprises the steps of: providing a compound of claim 17; deprotecting the hydroxyl residues of the 4-hydroxy-benzyl alcohol residue; and acylating the phenol residue.

20. A method of manufacture of R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te ester hydrogen fumarate or R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te ester hydrochloride hydrate, the method comprising the steps of; providing a compound of claim 17; deprotecting the hydroxyl residues of the 4-hydroxy-benzyl alcohol residue; and acylating the phenol residue.

21. A method of treating a patient suffering from urinary incontinence, which method comprises the step of administering to said patient an effective amount of a compound according to claim 1.

22. A method of treating a patient suffering from urinary incontinence, which method comprises the step of administering to said patient an effective amount of a compound according to claim 3.

23. A method of treating a patient suffering from urinary incontinence, which method comprises the step of administering to said patient an effective amount of a compound according to claim 5.

24. The method of any one of claims 21-23, wherein the urinary incontinence disorder is urge incontinence.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc